Convalescent plasma therapy in COVID-19 patients: a non-randomized case-control study with concurrent control
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Medical and Biological Research |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2022000100659 |
Resumo: | Convalescent plasma therapy has shown controversial results in coronavirus disease-19 (COVID-19) patients. We performed a non-randomized case-control study with contemporaneous controls in a hospital in southern Brazil. Patients were selected for treatment with convalescent plasma by medical decision and compared with patients who did not receive plasma and were hospitalized due to COVID-19 at the same time. The outcomes of interest were intensive care unit (ICU) admission and in-hospital death. Patients that received convalescent plasma had lower in-hospital mortality than patients that did not receive plasma (relative risk (RR) 0.48; 95% confidence interval (CI) 0.29 to 0.79) and these results were consistent after changing the subset of control patients. There were no differences regarding ICU admission between groups (RR=0.80; 95%CI: 0.47 to 1.35). In this study, patients that received convalescent plasma for COVID-19 had lower in-hospital mortality, but this finding requires further confirmation given the retrospective nature of the study. |
id |
ABDC-1_994776a8da3d20ba98acd9d0958be2a3 |
---|---|
oai_identifier_str |
oai:scielo:S0100-879X2022000100659 |
network_acronym_str |
ABDC-1 |
network_name_str |
Brazilian Journal of Medical and Biological Research |
repository_id_str |
|
spelling |
Convalescent plasma therapy in COVID-19 patients: a non-randomized case-control study with concurrent controlConvalescent plasmaCOVID-19Non-randomized trialConvalescent plasma therapy has shown controversial results in coronavirus disease-19 (COVID-19) patients. We performed a non-randomized case-control study with contemporaneous controls in a hospital in southern Brazil. Patients were selected for treatment with convalescent plasma by medical decision and compared with patients who did not receive plasma and were hospitalized due to COVID-19 at the same time. The outcomes of interest were intensive care unit (ICU) admission and in-hospital death. Patients that received convalescent plasma had lower in-hospital mortality than patients that did not receive plasma (relative risk (RR) 0.48; 95% confidence interval (CI) 0.29 to 0.79) and these results were consistent after changing the subset of control patients. There were no differences regarding ICU admission between groups (RR=0.80; 95%CI: 0.47 to 1.35). In this study, patients that received convalescent plasma for COVID-19 had lower in-hospital mortality, but this finding requires further confirmation given the retrospective nature of the study.Associação Brasileira de Divulgação Científica2022-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2022000100659Brazilian Journal of Medical and Biological Research v.55 2022reponame:Brazilian Journal of Medical and Biological Researchinstname:Associação Brasileira de Divulgação Científica (ABDC)instacron:ABDC10.1590/1414-431x2022e12235info:eu-repo/semantics/openAccessCacilhas,P.Caberlon,E.Angoleri,L.Fassina,K.Ribeiro,R.N.Pinto,L.C.eng2022-09-08T00:00:00Zoai:scielo:S0100-879X2022000100659Revistahttps://www.bjournal.org/https://old.scielo.br/oai/scielo-oai.phpbjournal@terra.com.br||bjournal@terra.com.br1414-431X0100-879Xopendoar:2022-09-08T00:00Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)false |
dc.title.none.fl_str_mv |
Convalescent plasma therapy in COVID-19 patients: a non-randomized case-control study with concurrent control |
title |
Convalescent plasma therapy in COVID-19 patients: a non-randomized case-control study with concurrent control |
spellingShingle |
Convalescent plasma therapy in COVID-19 patients: a non-randomized case-control study with concurrent control Cacilhas,P. Convalescent plasma COVID-19 Non-randomized trial |
title_short |
Convalescent plasma therapy in COVID-19 patients: a non-randomized case-control study with concurrent control |
title_full |
Convalescent plasma therapy in COVID-19 patients: a non-randomized case-control study with concurrent control |
title_fullStr |
Convalescent plasma therapy in COVID-19 patients: a non-randomized case-control study with concurrent control |
title_full_unstemmed |
Convalescent plasma therapy in COVID-19 patients: a non-randomized case-control study with concurrent control |
title_sort |
Convalescent plasma therapy in COVID-19 patients: a non-randomized case-control study with concurrent control |
author |
Cacilhas,P. |
author_facet |
Cacilhas,P. Caberlon,E. Angoleri,L. Fassina,K. Ribeiro,R.N. Pinto,L.C. |
author_role |
author |
author2 |
Caberlon,E. Angoleri,L. Fassina,K. Ribeiro,R.N. Pinto,L.C. |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Cacilhas,P. Caberlon,E. Angoleri,L. Fassina,K. Ribeiro,R.N. Pinto,L.C. |
dc.subject.por.fl_str_mv |
Convalescent plasma COVID-19 Non-randomized trial |
topic |
Convalescent plasma COVID-19 Non-randomized trial |
description |
Convalescent plasma therapy has shown controversial results in coronavirus disease-19 (COVID-19) patients. We performed a non-randomized case-control study with contemporaneous controls in a hospital in southern Brazil. Patients were selected for treatment with convalescent plasma by medical decision and compared with patients who did not receive plasma and were hospitalized due to COVID-19 at the same time. The outcomes of interest were intensive care unit (ICU) admission and in-hospital death. Patients that received convalescent plasma had lower in-hospital mortality than patients that did not receive plasma (relative risk (RR) 0.48; 95% confidence interval (CI) 0.29 to 0.79) and these results were consistent after changing the subset of control patients. There were no differences regarding ICU admission between groups (RR=0.80; 95%CI: 0.47 to 1.35). In this study, patients that received convalescent plasma for COVID-19 had lower in-hospital mortality, but this finding requires further confirmation given the retrospective nature of the study. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2022000100659 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2022000100659 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/1414-431x2022e12235 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Brasileira de Divulgação Científica |
publisher.none.fl_str_mv |
Associação Brasileira de Divulgação Científica |
dc.source.none.fl_str_mv |
Brazilian Journal of Medical and Biological Research v.55 2022 reponame:Brazilian Journal of Medical and Biological Research instname:Associação Brasileira de Divulgação Científica (ABDC) instacron:ABDC |
instname_str |
Associação Brasileira de Divulgação Científica (ABDC) |
instacron_str |
ABDC |
institution |
ABDC |
reponame_str |
Brazilian Journal of Medical and Biological Research |
collection |
Brazilian Journal of Medical and Biological Research |
repository.name.fl_str_mv |
Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC) |
repository.mail.fl_str_mv |
bjournal@terra.com.br||bjournal@terra.com.br |
_version_ |
1754302949014634496 |